Sensyne Health PLC Sensyne launches MagnifEye smartphone app

TIDMSENS

Sensyne Health PLC

14 January 2021

Sensyne Health launches MagnifEye smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI

MagnifEye(TM) uses a cloud-based deep learning algorithm to automate the accurate reading and analysis of lateral flow diagnostic tests, such as for COVID-19, providing standardised results in under 2 seconds

Oxford, U.K. 14 January 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI technology company, today announced the launch of MagnifEye, a new smartphone software application that uses deep machine learning AI to automate the accurate reading, beyond the human visible spectrum, and Big Data analysis of lateral flow diagnostic tests.

MagnifEye draws on research & development at Sensyne over the past two years in applying deep learning AI to the analysis of medical images and Big Data analysis of clinical results across large patient populations. The MagnifEye application was then built in response to the demand generated by the COVID-19 pandemic for the accurate and standardised reading of lateral flow tests used for disease surveillance across large populations and the Big Data analysis of results in real time. The IP underlying MagnifEye is the subject of a number of patent applications filed by the Company.

MagnifEye is marketed as a busines-to-business commercial product now being offered to lateral flow test manufacturers and healthcare providers that use lateral flow tests for disease surveillance across large populations, including in international markets. MagnifEye can be quickly trained to read and analyse individual lateral flow tests and has applications in human and animal health, including cancer, infectious disease and fertility, as well as plant pathogen and environmental testing. It can be used as a standalone smartphone application or incorporated into third party web or native software applications.

The key features and potential benefits of MagnifEye to lateral flow test manufacturers and healthcare providers that use them are:

-- Improved accuracy of reading - avoiding human error and reading beyond the human visible spectrum to reduce the number of false negative test results

   --    Fast response - provides lateral flow test results in under 2 seconds. 
   --    Reduced risk of fraud - identifying tests that have been tampered with 
   --    Automated provision of validated test results - securely linking to electronic health records 

-- Faster generation of epidemiological insights - using Big Data analytics with the capacity to analyse the data across very large populations

-- Improved security - encrypted and securely held data transfer and storage with links to healthcare providers and public health officials

-- Flexible - available in iOS, Android or web app formats, as an API or SDK (software development kit)

Lord (Paul) Drayson PhD FREng, CEO, said: "Applying Clinical AI to medical imaging has been an important R&D focus for Sensyne since formation and the Company has developed world-class deep learning AI capabilities in this area and has a collaboration with Bayer in the field of machine vision. Diagnostic testing has seen rapid progress over the past year, accelerated by responses to the COVID-19 pandemic. We have been working on developing a general capability to automate the reading of lateral flow tests in response to demand from commercial test manufacturers and healthcare providers. We look forward to working with these potential partners to apply this technology as rapidly as possible."

-ENDS-

For more information please contact:

 
  Sensyne Health ( www.sensynehealth.com             [phone] 
   )                                                  1845 
  Lord (Paul) Drayson PhD FREng, Chief Executive 
   Officer 
  Michael Norris, Interim Chief Financial 
   Officer 
 
   Dr Richard Pye, Chief Investment Officer 
  Consilium Strategic Communications                 [phone] 
  Mary-Jane Elliott 
  Sukaina Virji 
  Davide Salvi 
  [e-mail] 
 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAAFDFEDFEAA

(END) Dow Jones Newswires

January 14, 2021 02:00 ET (07:00 GMT)